221 related articles for article (PubMed ID: 30216221)
21. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
22. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer.
Sun Z; Adam MA; Kim J; Turner MC; Fisher DA; Choudhury KR; Czito BG; Migaly J; Mantyh CR
Colorectal Dis; 2017 Dec; 19(12):1058-1066. PubMed ID: 28586509
[TBL] [Abstract][Full Text] [Related]
23. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
25. Oncologic outcomes of neoadjuvant chemoradiation for locally advanced rectal cancer: a single-institution experience.
Leong YH; Leong CN; Tay GS; Sim R; Lopes G; Low W; Choo BA; Tey J
Ann Acad Med Singap; 2014 Dec; 43(12):569-75. PubMed ID: 25588915
[TBL] [Abstract][Full Text] [Related]
26. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
27. Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study.
Bergquist JR; Thiels CA; Shubert CR; Habermann EB; Hayman AV; Zielinski MD; Mathis KL
World J Surg; 2016 Feb; 40(2):447-55. PubMed ID: 26566779
[TBL] [Abstract][Full Text] [Related]
28. Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response.
Gahagan JV; Whealon MD; Phelan MJ; Mills S; Jafari MD; Carmichael JC; Stamos MJ; Zell JA; Pigazzi A
Surg Oncol; 2020 Mar; 32():35-40. PubMed ID: 31726418
[TBL] [Abstract][Full Text] [Related]
29. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.
Landi F; Espín E; Rodrigues V; Vallribera F; Martinez A; Charpy C; Brunetti F; Azoulay D; de'Angelis N
Int J Colorectal Dis; 2017 Feb; 32(2):255-264. PubMed ID: 27757541
[TBL] [Abstract][Full Text] [Related]
30. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
31. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
32. Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.
Sorenson E; Lambreton F; Yu JQ; Li T; Denlinger CS; Meyer JE; Sigurdson ER; Farma JM
J Surg Res; 2019 Nov; 243():242-248. PubMed ID: 31229791
[TBL] [Abstract][Full Text] [Related]
33. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
34. [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
Sun Y; Chi P; Xu B; Lin H; Lu X; Huang Y; Xu Z; Huang S; Jiang C
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jun; 17(6):556-60. PubMed ID: 24953361
[TBL] [Abstract][Full Text] [Related]
35. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
36. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
37. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Katz MS; Minsky BD; Saltz LB; Riedel E; Chessin DB; Guillem JG
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1363-70. PubMed ID: 16029794
[TBL] [Abstract][Full Text] [Related]
38. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
